A recent study reveals that people who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who end conventional lifestyle programs.
Research printed in a leading medical journal shows that while obese people frequently drop substantial amounts of their body weight while on the medication, the mass returns at an average rate of nearly a kilo each month once they quit.
"Users buying these medications must be cognizant of the danger of rapid rebound weight gain when the medication ends," stated researcher Dr. Susan Jebb.
That rate of regain suggests a return to original mass within about one and a half years.
Analyzing Therapies
The analysis, which examined 37 of studies involving thousands of patients, compared the effects of GLP-1 agonists with conventional dieting.
Scientists point out that people who shed pounds through lifestyle changes alone typically have a more gradual creep back—approximately 0.1 kg a month—after stopping.
Explaining the Rapid Regain
Doctors suggest the way of the injections accounts for the heightened regain.
These medications imitate a natural hormone called GLP-1, which controls hunger.
"Artificially providing the hormone levels far above than normal may cause the body to generate a reduced amount of its own natural hormone, and could reduce responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' means hunger is unsuppressed, making overeating far more likely."
A Chronic Condition?
The NHS advise the jabs for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Many experts contend that, due to the significant potential of relapse, the treatment is often ongoing.
This opinion is reinforced by drug manufacturers, who note that the findings "underscore the persistent nature of excess weight," similar to managing diseases like high blood pressure.
Patient Testimonies
People who have discontinued the medication report a intense resurgence of appetite.
"It felt as if something activating and I was suddenly starving," said a patient.
This difficulty is compounded if individuals have not established sustainable dietary or behavioural changes during therapy.
Growing Adoption
Survey data suggest that a significant number of adults in the UK have tried these injections in the past year, with interest remaining high.
- Use is more common among women than males.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
In conclusion, experts emphasize that while the jabs are powerful tools for weight loss, they are not a magic cure and maintained weight loss relies on combined lifestyle support.
